GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
Status:
Recruiting
Trial end date:
2025-11-30
Target enrollment:
Participant gender:
Summary
This research study is studying a drug called GDC-0084 as a possible treatment for
HER2-Positive Breast Cancer.
The drugs involved in this study are:
- GDC-0084
- Trastuzumab (Herceptin®)